TITLE

Clement seeks safe injection site study

AUTHOR(S)
Rynor, Becky
PUB. DATE
June 2007
SOURCE
CMAJ: Canadian Medical Association Journal;6/19/2007, Vol. 176 Issue 13, p1813
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article reports on the issuance of a call for research proposals to determine the validity of proposed injection sites by Health Canada in response to the demand of Federal Health Minister Tony Clement for proof of the efficacy of safe injection sites in Canada. The findings of the study will be used to help Clement decide whether to extend an exemption from federal drug law which allows Vancouver-based InSite safe injection site to continue its operations.
ACCESSION #
25360240

 

Related Articles

  • Clement seeks safe injection site study. Rynor, Becky // CMAJ: Canadian Medical Association Journal Supplement;6/19/2007, Vol. 176 Issue 13, p1813 

    The article reports on the call made by the Canadian Health Canada for research proposals that would support the proposition that safe injection sites are effective. The call was made as response to demand of Federal Health Minister Tony Clement for such proof. It states that the findings will...

  • Supervised Injection Sites: Health Canada Approves Vancouver Pilot Sites, but Concerns Remain. Kerr, Thomas // Canadian HIV/AIDS Policy & Law Review;Aug2003, Vol. 8 Issue 2, p18 

    Reports on the approval by the Health Canada of two pilot supervised injection sites (SIS) of the Vancouver Coastal Health Authority (VCHA) in Vancouver as of August 2003. Amount pledged by Health Canada to support the evaluation component of the project; Concerns on the SIS project; Structure...

  • Inadvertent injection of topical/nasal Adrenalin.  // Reactions Weekly;8/28/2010, Issue 1316, p5 

    The article reports on the "Dear Health Care Professional" letter issued by Health Canada about the risk of inadvertent injection of a topical/nasal formulation of epinephrine chloride due to similarities in its packaging compared with other injectable-use vials.

  • Harm-reduction advocates lobby for safe injection site in Ottawa. Ascah, Adrienne // Capital Xtra (Ottawa);10/10/2013, Issue 260, p12 

    The article reports on the lobbying of Ottawa Hospital head of infectious disease Mark Tyndall with Sandy Hill Community Health Centre to apply to Health Canada for the plan to build a safe injection site in Ottawa, Canada.

  • Transdermal fentanyl and respiratory arrest in adolescents.  // WHO Drug Information;2004, Vol. 18 Issue 4, p275 

    Focuses on the report received by Health Canada on two cases of death suspected of being associated with the use of transdermal fentanyl system (Duragesic) prescribed off-level to adolescents. Indication of Duragesic for the management of chronic pain in patients requiring continuous opioid...

  • IV use of Nimotop oral capsules may cause adverse events.  // Reactions Weekly;10/1/2005, Issue 1071, p2 

    Reports that Bayer Healthcare, in collaboration with Health Canada, is advising healthcare professionals that inappropriate IV administration of the contents of oral Nimotop (nimodipine) capsules has been temporarily associated with serious, life-threatening or fatal adverse events. Information...

  • Health Canada warns against using Emagrece Sim and Herbathin.  // Reactions Weekly;3/4/2006, Issue 1091, p3 

    Reports that Health Canada has issued a warning against the use of weight-loss products Emagrece Sim and Herbathin because of the possibility that they contain harmful substances. Impact of these products on mental alertness and physical coordination; Need for medical supervision when...

  • Distant spread of toxin possible with Botox, says company.  // Reactions Weekly;1/24/2009, Issue 1236, p2 

    The article reports on a Dear Health Care professional letter issued by Allergan advising of a possibility of distant spread of toxin linked with botulinum toxin A injection. According to the company, the product monographs for Botox and Botox Cosmetic have been updated to include the additional...

  • IV naturopathic drugs: Health Canada warns of health risks.  // Reactions Weekly;10/21/2006, Issue 1124, p2 

    The article reports that Health Canada has warned consumers and health practitioners in October 2006 against the intravenous naturopathic products bismacine, dioxychlor and sulfoxime since they pose a major health risk. According to the agency, bismacine contains high amounts of bismuth which...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics